Hydroxykynurenine
|
Basic information |
| Metabolite name | Hydroxykynurenine |
 | HMDB0000732 |
 |
C02794 |
 |
89 |
| Synonyms | Dl-3-Hydroxy-kynurenine; |
| No. of studies | 27 |
|
Basic information |
| Metabolite name | Hydroxykynurenine |
| HMDB0000732 |
|
C02794 |
|
89 |
| Synonyms | Dl-3-Hydroxy-kynurenine; |
| No. of studies | 27 |
|
Relationship between Hydroxykynurenine and depression (count: 27) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M037 | Type2 | placebo treatment group four-week vs. baseline | Serum | Human | Up |
| Study M046 | Type1 | LPS group vs. control group | Dorsal hippocampus | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Central amygdala | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Nucleus accumbens | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Brain | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Plasma | C57BL/6N mouse | Up |
| Study M1049 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1059 | Type1 | CRS group vs. control group | Cecum | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Striatum | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Cortex | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Serum | Wistar rat | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Colon | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS group vs. control group | Serum | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1108 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Up |
| Study M1108 | Type1 | CRS group vs. control group | Serum | C57/6 J mouse | Up |
| Study M1108 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Serum | C57/6 J mouse | Down |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M126 | Type1 | LPS group vs. control group | Brain | CD-1 mouse | Up |
| Study M151 | Type1 | Female FSL group vs. Female FRL group | Brain | Sprague-Dawley rat | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M627 | Type1 | CUMS group vs. control group | Cortex | Sprague-Dawley rat | Up |
| Study M627 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M659 | Type1 | LPS group vs. control group | Cerebral cortex | C57BL/6J mouse | Up |
| Study M659 | Type1 | LPS group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M672 | Type2 | SMG + paroxetine group vs. SMG group | Urine | Sprague-Dawley rat | Up |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M724 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type2 | CUMS + middle dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M787 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Up |
| Study M879 | Type1 | unipolar depression group vs. control group | Plasma | Human | Down |
| Study M884 | Type1 | CSDS group vs. control group | Urine | C57BL/6J mouse | Up |
| Study M884 | Type1 | CSDS group vs. control group | Ileum | C57BL/6J mouse | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Serum | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Faece | C57BL/6 mouse | Down |